Citius Oncology Inc (CTOR)
Citius Oncology, Inc. is a NASDAQ-listed common stock company focused on developing and commercializing targeted oncology therapies. Its pipeline includes LYMPHIR, an orphan indication being developed for adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare type of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey, and operates as a subsidiary of Leonard-Meron Biosciences, Inc. As a healthcare company in the biotechnology industry, Citius Oncology’s activities center on advancing cancer-focused treatments through development and commercialization efforts.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CTOR
|
$1.27
|
11.5% Upside
|
Fair
|
$4
|
250.9% Upside
|
Bargain
|
Weak
|
0.0%
|
December 17, 2026
|
3.0x
|
17.0x
|
118.5 M
|
114.2 M
|
8.6%
|
29.3%
|
-1.9
|
42.1%
|
